Comparative Pharmacology
Head-to-head clinical analysis: FOSCARNET SODIUM versus VITRASERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSCARNET SODIUM versus VITRASERT.
FOSCARNET SODIUM vs VITRASERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Foscarnet is an organic analog of inorganic pyrophosphate that selectively inhibits the DNA polymerase activity of herpesviruses, including cytomegalovirus (CMV) and herpes simplex virus (HSV), at the pyrophosphate binding site without requiring activation by thymidine kinase. It also inhibits HIV reverse transcriptase.
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
Induction: 60 mg/kg IV every 8 hours for 14–21 days, followed by maintenance: 90–120 mg/kg IV once daily. Infuse at no more than 1 mg/kg/min via central or peripheral line.
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
None Documented
None Documented
Terminal elimination half-life is approximately 48 hours (range 24-88 hours), reflecting prolonged intracellular retention; clinical context necessitates dose adjustment for renal impairment and monitoring of renal function.
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Primarily excreted unchanged by the kidney via glomerular filtration and tubular secretion; >80% of dose recovered in urine within 24 hours; minimal biliary or fecal excretion (<5%).
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Category A/B
Category C
Antiviral
Antiviral